Litcius/Paper detail

Brd4-p300 inhibition downregulates Nox4 and accelerates lung fibrosis resolution in aged mice

Yan Y. Sanders, Xing Lyv, Qihou Zhou, Zheyi Xiang, D. Stanford, Sandeep Bodduluri, Steven M. Rowe, Victor J. Thannickal

2020JCI Insight69 citationsDOIOpen Access PDF

Abstract

Tissue regeneration capacity declines with aging in association with heightened oxidative stress. Expression of the oxidant-generating enzyme, NADPH oxidase 4 (Nox4), is elevated in aged mice with diminished capacity for fibrosis resolution. Bromodomain-containing protein 4 (Brd4) is a member of the bromodomain and extraterminal (BET) family of proteins that function as epigenetic "readers" of acetylated lysine groups on histones. In this study, we explored the role of Brd4 and its interaction with the p300 acetyltransferase in the regulation of Nox4 and the in vivo efficacy of a BET inhibitor to reverse established age-associated lung fibrosis. BET inhibition interferes with the association of Brd4, p300, and acetylated histone H4K16 with the Nox4 promoter in lung fibroblasts stimulated with the profibrotic cytokine, TGF-β1. A number of BET inhibitors, including I-BET-762, JQ1, and OTX015, downregulate Nox4 gene expression and activity. Aged mice with established and persistent lung fibrosis recover capacity for fibrosis resolution with OTX015 treatment. This study implicates epigenetic regulation of Nox4 by Brd4 and p300 and supports BET/Brd4 inhibition as an effective strategy for the treatment of age-related fibrotic lung disease.

Topics & Concepts

BromodomainNOX4BRD4EpigeneticsPulmonary fibrosisCancer researchFibrosisHistoneChemistryBET inhibitorBiologyCell biologyOxidative stressNADPH oxidaseMedicineInternal medicineBiochemistryGenePeptidase Inhibition and AnalysisProtein Degradation and InhibitorsMultiple Myeloma Research and Treatments